Evaluating novel therapies and circulating tumor DNA (ctDNA) as a marker of response in curatively treated gastrointestinal cancers with microscopic residual disease.

被引：1
|
作者：
Mukherji, Reetu
Noel, Marcus Smith
He, Aiwu Ruth
Weinberg, Benjamin Adam
Weiner, Louis M.
Marshall, John
机构：
[1] Georgetown Univ, Ruesch Ctr Cure Gastrointestinal Canc, Lombardi Comprehens Canc Ctr, Washington, DC USA
[2] Georgetown Univ, Lombardi Comprehens Canc Ctr, Washington, DC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 3_SUPPL期
关键词：
3282-415-6705; 613-545-552; 130-540-543; 261-492-11294; 261-492-341; 283-237-255; 261-492-3532-2370; 17; 6; 4; 3; 2; 3604;
D O I：
10.1200/JCO.2024.42.3_suppl.TPS765
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：TPS765 / TPS765
页数：1
相关论文
共 50 条
  • [41] Circulating tumor DNA as a marker of minimal residual disease following local treatment of metastases from colorectal cancer
    Boysen, Anders K.
    Pallisgaard, Niels
    Andersen, Christina S. A.
    Spindler, Karen-Lise G.
    ACTA ONCOLOGICA, 2020, 59 (12) : 1424 - 1429
  • [42] Molecular residual disease (MRD) detection using bespoke circulating tumor DNA (ctDNA) assays in localized soft tissue sarcoma (STS)
    Salawu, Abdulazeez
    Demicco, Elizabeth
    Chung, Peter W. M.
    Feeney, Jordan
    Spickard, Erik
    Rathore, Richa
    Lee, Jasmine
    Wong, Philip
    Malone, Eoghan Ruadh
    Catton, Charles
    Arones, Limore
    Phillips, Madeline J.
    Ferguson, Peter Charles
    Wunder, Jay
    Tin, Tony
    Sethi, Himanshu
    Liu, Minetta C.
    Shultz, David Benjamin
    Razak, Albiruni Ryan Abdul
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [43] Finding Waldo: The Evolving Paradigm of Circulating Tumor DNA (ctDNA)-Guided Minimal Residual Disease (MRD) Assessment in Colorectal Cancer (CRC)
    Chakrabarti, Sakti
    Kasi, Anup Kumar
    Parikh, Aparna R.
    Mahipal, Amit
    CANCERS, 2022, 14 (13)
  • [44] Novel Circulating Tumor Dna (CTDNA) Based Ddpcr Drop-OFF Assays for Improved Minimal Residual Disease (MRD) Monitoring in Acute Myeloid Leukemia (AML)
    Rausch, Christian
    Ziemann, Frank
    Schneider, Stephanie
    Subklewe, Marion
    Spiekermann, Karsten
    Thorley, Maja Rothenberg
    Metzeler, Klaus
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 107 - 107
  • [45] Novel circulating tumor DNA (ctDNA) based ddPCR drop-off assays for improved Minimal Residual Disease (MRD) monitoring in Acute Myeloid Leukemia (AML)
    Rausch, C.
    Ziemann, F.
    Schneider, S.
    Subklewe, M.
    Spiekermann, K.
    Rothenberg-Thurley, M.
    Metzeler, K. H.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 252 - 252
  • [46] Circulating tumor DNA (ctDNA) residual and dynamics of ctDNA clonality indicated therapeutic efficacy of sintilimab plus docetaxel in previously treated advanced non-small cell lung cancer
    Wang, Z.
    Han, X.
    Guo, J.
    Tang, X.
    Zhu, C.
    Zhu, H.
    Zhu, D.
    Zhang, X.
    Meng, X.
    ANNALS OF ONCOLOGY, 2021, 32 : S1380 - S1380
  • [47] Circulating Tumor DNA-Defined Minimal Residual Disease in Solid Tumors: Opportunities to Accelerate the Development of Adjuvant Therapies
    Dasari, Arvind
    Grothey, Axel
    Kopetz, Scott
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (35) : 3437 - +
  • [48] Correlation of somatic genomic alterations between tissue genomics and circulating tumor DNA (ctDNA) employing next generation sequencing (NGS) analysis in lung and gastrointestinal cancers
    Toor, M. M.
    Bahaj, W.
    Ahmed, Z.
    Kujtan, L.
    Pluard, T. J.
    McNally, M. E.
    Cummings, L. S.
    Island, E.
    Forster, J.
    Kennedy, K. F.
    Subramanian, J.
    Masood, A.
    ANNALS OF ONCOLOGY, 2017, 28
  • [49] Performance characteristics of a tumor-informed circulating tumor DNA (ctDNA) minimal residual disease (MRD) assay in invasive bladder cancer in clinical practice.
    Mehler, Shoshana
    Guilbeau, Seth
    Somer, Shmuel
    Reed, Kevin
    Greene, Heather
    Vaena, Daniel A.
    Grothey, Axel
    Somer, Brad
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [50] Characteristics of genomic alterations in circulating tumor DNA (ctDNA) in patients (Pts) with advanced gastrointestinal (GI) cancers in nationwide large-scale ctDNA screening:SCRUM-Japan Monstar-Screen
    Nakamura, Yoshiaki
    Fujisawa, Takao
    Kadowaki, Shigenori
    Takahashi, Naoki
    Goto, Masahiro
    Yoshida, Kazuhiro
    Kawakami, Takeshi
    Esaki, Taito
    Oki, Eiji
    Nishida, Naohiro
    Nishina, Tomohiro
    Komatsu, Yoshito
    Ohta, Takashi
    Kuramoto, Naomi
    Horasawa, Satoshi
    Sakamoto, Yasutoshi
    Taniguchi, Hiroya
    Yoshino, Takayuki
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
12345